[BioS] AbClon transfers rights to TIGIT antibody co-developed with Yuhan
Predicted impact: Low
TIGIT antibody rights transfer; deal size not disclosed.
Yuhan유한양행
000100 · KOSPI · ₩000100 · 유한양행
₩74,700▼ ₩2,600 (3.36%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −36.26%
- Market cap
- ₩5.5T
- Enterprise value
- ₩5.4T
- P/E
- 23.2×
- P/B
- 2.3×
- Dividend yield
- 0.8%
- ROE
- 9.9%
- Net margin
- 10.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−42.2% from the high
₩65,000Today: ₩73,400 – ₩77,800₩129,200
Returns
- 1W−11.1%
- 1M+2.3%
- 3M+0.9%
- 6M−18.4%
- YTD−33.5%
- 1Y−36.3%
- Volume today
- 317,305
- 1.1× the 20-day average
- Traded today
- ₩24B
- Listed shares
- 73,615,781
- EPS (12 months)
- ₩3,221
- Earnings yield 4.3%
AI research · Update noteYuhan Q3 2026 Preliminary Results: Operating Profit Up 44.2% but Down 43.4% From Q2The results are mixed.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 51: in the news.
- SentimentPositiveNews: Partnership news is positive, though the rights transfer is a neutral business event. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactSome21 news items and filings in two weeks; 0 rated high impact, 3 medium.
- StreetSteady2 brokers, average target 61% from the price; last 30 days: 0 raised, 0 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 29: sell ₩187M at the close (0.8% of 20-day average trading value)
On its 14 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 4.7% of trading value and pointed the same way 9 of 14 times.
- -2× KODEX 200 Futures Inverse 2X −₩134M
- 2× KODEX Leverage −₩16M
- 2× TIGER 200IT Leverage −₩9.1M
- -1× KODEX Inverse −₩8M
- 2× TIGER Leverage −₩6.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2000.1%
- TIGER 2000.1%
- KODEX 200TR0.1%
- KODEX Leverage2×0.1%
- RISE 2000.1%
- ACE 2000.1%
- KIWOOM 200TR0.1%
- PLUS 2000.1%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 74,900
Basis +0.27% · implied rate +7.0%
Open interest 152,746 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Yuhan stock overview
Yuhan (유한양행, KRX: 000100) is listed on KOSPI, in the Biotech & Pharma sector. Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its shares closed at ₩74,700 on Oct 29, 2026, down 3.36% on the day, giving it a market value of ₩5.5T.
Key facts
- Market cap
- ₩5.5T
- Sector
- Biotech & Pharma
- Latest price change
- −3.36%
- As of
- Oct 29, 2026
- Main business
- Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods.
Quick answers about Yuhan
- What does Yuhan do?
- Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its main products include Lazertinib (Lazcluze), Antiflamin, Bicom C, Duowell, Kofsyrup, and Elena. The company also has a health care division selling household products such as Yuhan Lox bleach, and an overseas business that exports products and supplies active pharmaceutical ingredients through its subsidiary Yuhan Chemical.
- What is the market cap of Yuhan?
- The market capitalisation of Yuhan was ₩5.5T at the close on Oct 29, 2026.
- What is the analyst target price for Yuhan?
- The average target price of 2 brokers covering Yuhan is ₩120,000 (range ₩110,000 to ₩130,000), 60.6% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Yuhan?
- According to the latest official filings, the largest reported holders are National Pension Service (6.83%, as of Mar 3, 2026); BlackRockFundAdvisors (6.50%, as of Aug 10, 2026); GK Asset (5.03%, as of May 11, 2026).
- When is the next earnings report from Yuhan?
- Korean companies rarely announce results dates in advance. Based on when Yuhan filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Yuhan?
- Yes. The National Pension Service held 6.83% of Yuhan shares as of Mar 3, 2026.
Company profile
Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its main products include Lazertinib (Lazcluze), Antiflamin, Bicom C, Duowell, Kofsyrup, and Elena. The company also has a health care division selling household products such as Yuhan Lox bleach, and an overseas business that exports products and supplies active pharmaceutical ingredients through its subsidiary Yuhan Chemical.
Written by AI from the company's latest annual report.
- Korean name
- 유한양행
- Sector
- Biotech & Pharma
- CEO
- 대표이사 조욱제
- Founded
- Jun 1926
- Listed
- Nov 1962
- Listed shares
- 73,615,781
- Fiscal year ends
- Month 12
- Website
- www.yuhan.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
- SK Bioscience302440 · ₩2.5T₩32,200+0.16%
Recent news
Yuhan and Boehringer Ingelheim Korea join hands to drive digital healthcare innovation
Predicted impact: Low
Digital healthcare partnership with Boehringer Ingelheim Korea; same partnership covered repeatedly in recent days.
Yuhan, Boehringer Ingelheim expand parternship for broader healthcare collaboration
Predicted impact: Low
Expanded Boehringer healthcare partnership already reported in recent days; no financial terms given.
Recent filings
See all- Investor relations (IR) eventOct 30, 2026
- Preliminary earningsOct 28, 2026
- Investor relations (IR) eventOct 27, 2026
- Insider shareholding reportOct 2, 2026
- Major sales or supply contractSep 15, 2026
Titles in Korean until English translations are added.
Also known as: Yuhan / 유한양행 / 000100 / KRX:000100
Source: KRX statistical information